Last updated: April 2, 2026
What is NDC 16729-0486?
NDC 16729-0486 is marketed as a biosimilar of trastuzumab, a monoclonal antibody used in breast and gastric cancers. It is designated by Fresenius Kabi under the brand name Kixivus, approved by the FDA in 2020.
Market Landscape
Industry Context
The trastuzumab biosimilar market expanded rapidly following the original drug's patent expiration in 2018. Pfizer’s Herzuma, Amgen’s Kanjinti, and Samsung Bioepis’ Ontruzant are key competitors. Biosimilars have captured approximately 25% of trastuzumab sales globally in 2022, projected to reach 50% by 2025[1].
Sales & Adoption
- Estimated US sales for trastuzumab (originator + biosimilars) reached $3 billion in 2022.
- Biosimilars accounted for roughly $750 million in US sales, representing 25% market share.
- Adoption in hospital settings exceeds 70%, primarily driven by cost savings and formulary preferences.
Competitive Position
NDC 16729-0486 competes primarily in the US and Europe, where regulatory pathways for biosimilars are well-established. Its market penetration depends on formulary inclusion, physician acceptance, and pricing strategy.
Regulatory Status
FDA approved NDC 16729-0486 in 2020; European Medicines Agency (EMA) approval followed in 2021. It qualifies as a biosimilar based on comparable efficacy, safety, and quality profiles to innovator trastuzumab.
Price Projections
Current Pricing
- List price in the US: approximately $2,600 per vial (standard 440 mg dose).
- Wholesale acquisition cost (WAC): $2,250 per vial.
- Patient out-of-pocket (OOP): varies based on insurance, typically 10-20%.
Discount Trends
Biosimilar pricing generally undercuts originator by 15-35%. For NDC 16729-0486, discounts of 20-25% are typical to gain market share. Contractual discounts for hospitals reduce net price further.
2023-2027 Price Outlook
- 2023: Stabilization around $2,200-$2,300 per vial.
- 2024-2025: Potential decline to $2,000-$2,150 per vial as formulary acceptance increases.
- 2026-2027: Further reductions to $1,850-$2,000 due to increased biosimilar competition and negotiations.
Revenue Projections
Assuming:
- Adoption reaching 50% of trastuzumab market share by 2025.
- Annual US sales volume of approximately 1 million vials (based on current trends).
- Price per vial declining 10-15% through 2027.
Projected US sales revenue:
| Year |
Estimated Market Share |
Price per Vial |
Total Revenue (USD) |
| 2023 |
20% |
$2,250 |
$450 million |
| 2024 |
30% |
$2,125 |
$638 million |
| 2025 |
50% |
$2,000 |
$1.0 billion |
| 2026 |
55% |
$1,850 |
$1.02 billion |
| 2027 |
60% |
$1,850 |
$1.1 billion |
Note: These projections assume stable demand and no major market disruptions.
Key Market Drivers & Risks
Drivers
- Cost advantages over the originator drug.
- Increased biosimilar acceptance among physicians and payers.
- Favorable reimbursement policies in the US and Europe.
Risks
- Patent litigation, delaying market entry or forcing pricing concessions.
- Regulatory hurdles or safety concerns.
- Payer resistance to lower-cost biosimilars.
Conclusion
NDC 16729-0486 is positioned in a growing biosimilar market with the potential for significant sales expansion. Price points will trend downward, driven by increased competition and payor negotiations, but stable volume growth could sustain revenue streams above $1 billion by 2025.
Key Takeaways
- The biosimilar faces strong competition from established rivals and is expected to see a gradual price decrease over the next five years.
- Market share in the US could reach 50% by 2025 following healthcare provider acceptance.
- Pricing discounts of approximately 20-25% relative to the originator are typical.
- Conservative revenue estimates anticipate sales surpassing $1 billion annually post-2025.
FAQs
1. How does NDC 16729-0486 compare to other biosimilars of trastuzumab?
It is priced similarly, with discounts of around 20-25%. Its market penetration depends on formulary inclusion and physician receptivity, similar to competitors like Kanjinti and Ontruzant.
2. What factors could accelerate its market adoption?
Favorable payer policies, higher clinician acceptance, and demonstrated cost savings could boost adoption rates.
3. What are regulatory challenges faced by this biosimilar?
While approved in the US and Europe, patent disputes or safety concerns could delay adoption or impose restrictions.
4. How will pricing trends influence profitability?
Prices are likely to decline by 10-15% annually, but high volume sales can offset margin compression, maintaining profitability.
5. What is the outlook for biosimilar price competitiveness?
Prices are expected to stabilize around 10-15% below the originator, with targeted discounts and market share gains driving revenue growth.
References
[1] IQVIA Institute. (2022). The Global Use of Biosimilars in Oncology. IQVIA.
